Edwards Lifesciences Corporation (EW) Intrinsic Value & DCF Valuation
Medical - Devices · NYSE
Current Price
$84.37
Intrinsic Value
$93.23
+9.5% margin of safety
What Is Edwards Lifesciences Corporation's Intrinsic Value?
As of 2026-09-11, the base-case DCF model estimates the intrinsic value of Edwards Lifesciences Corporation (EW) at $93.23 per share, compared with a market price of $84.37, a margin of safety of +9.5%. The base case assumes 11.6% annual free cash flow growth and a 10.0% discount rate.
Across the sensitivity grid the estimate spans $78.28 to $110.18. Intrinsic value is an estimate built on assumptions, not a fact. A higher discount rate or slower growth pushes the estimate down, while stronger cash flow growth lifts it.
How the DCF works · Recalculate with your own assumptions · What is intrinsic value?
Is Edwards Lifesciences Corporation (EW) Undervalued?
At $84.37, EW trades about 9.5% below the base-case intrinsic value estimate. That is a real discount, but it stays short of the 30% margin of safety required before calling a stock undervalued.
COMPETITIVE MOAT
↑Strong TAVR Market Leadership
Edwards Lifesciences holds a dominant position in the transcatheter aortic valve replacement (TAVR) market. This leadership is built on years of innovation and clinical data.
↑Extensive Clinical Data & Physician Training
The company has amassed a vast amount of clinical evidence supporting its devices. It also invests heavily in training physicians, creating high switching costs.
↑Intellectual Property & R&D Pipeline
Edwards possesses a robust portfolio of patents protecting its technologies. Continuous investment in research and development fuels its pipeline of next-generation devices.
INVESTMENT RISKS
↓Currency Fluctuations Impact
As a global company, Edwards Lifesciences is exposed to foreign currency exchange rate volatility. This can negatively affect reported earnings and revenue.
↓Technological Disruption
Emerging technologies or alternative treatment modalities could potentially disrupt the market for current cardiovascular devices.
↓Reimbursement Policy Changes
Changes in healthcare reimbursement policies by governments or private insurers could impact the adoption and profitability of Edwards' products.
Base case
EW base case valuation
Intrinsic Value
$93.23
Margin of safety
+9.5%
Expected annual return
+2.0%
Base case assumptions: 11.6% annual growth, 10.0% discount rate, 30x exit multiple, 5 year projection. Data as of 2026-09-11.
This base case uses default assumptions and is not financial advice. The intrinsic value changes significantly when the growth rate or discount rate changes. Open the calculator to set your own assumptions and see the full sensitivity range.
Customize the EW valuation
Adjust the growth rate, discount rate, and exit multiple to see how the intrinsic value and margin of safety for Edwards Lifesciences Corporation respond.
Open DCF Calculator for EWCompany Overview
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
Financial Metrics — EW Stock Valuation Data
Revenue/Share (TTM)
$11.30
FCF/Share (TTM)
$2.49
ROIC (TTM)
10.2%
ROE (TTM)
9.7%
P/FCF
33.9x
EV/EBITDA
30.1x
FCF Yield
2.95%
Debt/Equity
0.07x
Based on trailing twelve-month data, EW shows a free cash flow per share of $2.49 and a ROIC of 10.2%, key inputs for stock valuation using the DCF method. The P/FCF ratio of 33.9x and FCF yield of 2.95% are important context metrics when evaluating EW's stock valuation relative to peers.
Frequently Asked Questions
What is the intrinsic value of EW?
Edwards Lifesciences Corporation currently generates $2.49 in free cash flow per share. At the current price of $84.37, a DCF model would discount these cash flows at an appropriate WACC and apply a terminal growth rate to arrive at an intrinsic value. The result depends heavily on your growth and discount rate assumptions — a 1% change in WACC typically shifts the fair value estimate by 10-15%. In MiniValuator the model uses a single discount rate that you can edit directly, 10% by default, rather than a computed WACC.
Is EW undervalued?
EW trades at a P/FCF ratio of 33.9x with a free cash flow yield of 2.95%. This P/FCF is in a moderate range. However, whether EW is truly undervalued requires comparing the DCF intrinsic value to the current market price and evaluating whether the margin of safety is sufficient for your risk tolerance.
How do I value EW stock using DCF?
To perform a DCF valuation on Edwards Lifesciences Corporation: (1) Start with the trailing free cash flow per share ($2.49) as the base, (2) project future FCF growth over 5-10 years based on Medical - Devices industry trends and company fundamentals, (3) apply a discount rate (WACC) reflecting EW's risk profile — with a debt-to-equity of 0.07x, capital structure is an important factor, and (4) add a terminal value for cash flows beyond the projection period.
What is DCF valuation and how does it apply to EW?
DCF (Discounted Cash Flow) estimates what a company is worth today based on its future cash generation. For Edwards Lifesciences Corporation, this means projecting how much free cash flow the company will produce over the next 5-10 years, shaped by Medical - Devices trends, then discounting those amounts to today's dollars. EW's ROIC of 10.2% shows moderate capital returns.
How does WACC affect EW stock valuation?
WACC (Weighted Average Cost of Capital) is the discount rate in a DCF model — it reflects the minimum return investors require. For EW, with a debt-to-equity ratio of 0.07x, the capital structure directly influences WACC. A 1% increase in WACC typically reduces the intrinsic value by 10-15%. At an EV/EBITDA of 30.1x, the market's implied discount rate can be reverse-engineered for comparison. In MiniValuator you set this discount rate yourself as a single editable number, 10% by default, instead of computing a formal WACC.
Learn More
- See EW PE Valuation → — Earnings-based stock valuation using PE ratio analysis
- DCF Methodology — Step-by-step guide to discounted cash flow analysis
- PE Methodology — Guide to PE ratio stock valuation
- WACC — Understanding the discount rate used in DCF
- Margin of Safety — How to evaluate downside protection
- Intrinsic Value — How to evaluate stock fair value
- How to Calculate Intrinsic Value — Complete guide for investors
Related Valuations
All Healthcare valuationsDCF and P/E value EW with different methods and assumptions, so the two conclusions can differ. Compare the P/E fair value.
Price as of 2026-09-11. Financial data from Financial Modeling Prep (trailing twelve months) · Valuation methodology by Charlie Wang.
This is an estimate, not investment advice.